Market Research
HCP positioning and branding
Patient and consumer branding
Business development / project valuation
Forecasting and launch planning
Scientific dissemination and KOL management
Business Biography
I began my professional healthcare career in 1996 as an MBA intern at Procter & Gamble’s Pharmaceutical division
(which alas no
longer exists). Prior to that I worked in sales in unrelated fields (publishing and landscape maintenance, go figure). I had applied for internships in both professional and consumer products and thought I was to be working on Joy dishwashing liquid. Imagine my surprise when I got a package with this book in it, which was to change my life forever
Apparently the answer for me was Yes
I received an offer from P&G at the end of the summer and have not looked back since.
My in-line marketing experience began with the launch of the bisphosphonate Actonel in 1997. Since that time I have launched franchises (Gintuit), line extensions (Zyrtec-D), additional indications (pediatric and monotherapy for Keppra), and led phase I/II programs (OP-1). My experience has also included global activities both as the global lead (Gintuit, OP-1) and as the lead market for a global franchise based outside of the US (Keppra, Rebif, Zyrtec). I have managed teams since 2002, supervising as many as nine marketing professionals.
From 2005 until 2009, I worked for Stryker Biotech, mostly recently as the Senior Director of Strategic Marketing. The position focused on the long term strategy of the division, mixing business development with management of their upstream development programs in osteoarthritis, degenerative disc disease and kidney failure, including a research collaboration with Joslin DiabetesCenter. Prior to this, I led marketing activities globally for OP-1, which had limited approvals at the time and was forecast to have peak year sales of over $500 million had it received full approval.
Stryker’s Biotech division had a rather ignominious end. The FDA brought OP-1 to an advisory board for spinal fusion but with little chance of approving it, as the clinical trials missed their primary endpoints. Soon after, the DOJ brought a felony misbranding charge to the division and indicated several people. It was settled for a misdemeanor charge and the indictments were dropped, but by then the division had been sold to Olympus, which has since shut it down completely. I was laid off in 2009, along with about 30% of the home office.
Following my layoff I joined Organogenesis, one of the world’s leading regenerative medicine companies. I championed the launch of their Living Cellular technology in the oral health space (primarily dental, but medical as well). The market was completely new to Organogenesis, which is primarily based in chronic would care. The successful launch of Gintuit in March 2012 represents the first launch of a cellular product in dentistry and the first approval of manufactured cellular product by CBER. It was a very interesting position and an excellent team that built all of the marketing strategy and sales infrastructure from the ground up (and without a lot of money). Unfortunately, Gintuit did not achieve profitability by the end of 2013 when CMS cut reimbursement for high end wound care treatments significantly and Organogenesis was forced to shut Gintuit down, along with R&D, clinical, and several other groups, in order to remain afloat.
You can review my complete resume here.
I also highlight a number of projects during my career here.
UA-50643418-1